What do pregnancy data indicate about the risk of birth defects after first-trimester exposure to lamivudine + zidovudine?

Pregnancy data indicate no malformative toxicity with lamivudine or zidovudine and suggest birth defects are unlikely, based on over 3,000 first-trimester exposure outcomes for each drug, including over 2,000 involving both.